GuoLine Advisory Pte Ltd Has $29.81 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

GuoLine Advisory Pte Ltd boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 20.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 346,500 shares of the company’s stock after buying an additional 58,900 shares during the quarter. Novo Nordisk A/S makes up 3.1% of GuoLine Advisory Pte Ltd’s holdings, making the stock its 17th biggest holding. GuoLine Advisory Pte Ltd’s holdings in Novo Nordisk A/S were worth $29,806,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of NVO. Natixis Advisors LLC raised its position in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares during the last quarter. Norman Fields Gottscho Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S in the fourth quarter valued at $86,000. Talbot Financial LLC acquired a new position in Novo Nordisk A/S during the 4th quarter worth about $4,066,000. Finally, Zions Bancorporation N.A. raised its position in shares of Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on NVO. BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Stock Down 4.0 %

Novo Nordisk A/S stock opened at $81.27 on Wednesday. The firm has a market capitalization of $364.70 billion, a price-to-earnings ratio of 26.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The firm’s fifty day moving average price is $99.26 and its two-hundred day moving average price is $118.18. Novo Nordisk A/S has a 1-year low of $80.05 and a 1-year high of $148.15. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.